Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis | Zendy

Paolo Spagnolo | Zendy; Michael Kreuter | Zendy; Toby M. Maher | Zendy; Wim Wuyts | Zendy; Francesco Bonella | Zendy; Tamera J. Corte | Zendy; Stefan Kopf | Zendy; Derek Weycker | Zendy; Klaus-Uwe Kirchgaessler | Zendy; Christopher J. Ryerson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis

Author(s) -

Paolo Spagnolo,

Michael Kreuter,

Toby M. Maher,

Wim Wuyts,

Francesco Bonella,

Tamera J. Corte,

Stefan Kopf,

Derek Weycker,

Klaus-Uwe Kirchgaessler,

Christopher J. Ryerson

Publication year - 2018

Publication title -

respiration

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.264

H-Index - 81

eISSN - 1423-0356

pISSN - 0025-7931

DOI - 10.1159/000489668

Subject(s) - medicine , metformin , diabetes mellitus , population , placebo , idiopathic pulmonary fibrosis , gastroenterology , type 2 diabetes , post hoc analysis , endocrinology , lung , pathology , alternative medicine , environmental health

Diabetes mellitus is a possible risk factor for the development of idiopathic pulmonary fibrosis (IPF), yet the effect of antidiabetic therapy on the course of IPF is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research